• Publications
  • Influence
Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer
We conducted a genome-wide association study on 969 bladder cancer cases and 957 controls from Texas. For fast-track validation, we evaluated 60 SNPs in three additional US populations and validatedExpand
  • 229
  • 18
Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer.
MicroRNAs (miRNA) are small noncoding RNA molecules involved in a diversity of cellular functions. Although it has been reported that global suppression of the miRNA biogenesis pathway leads toExpand
  • 241
  • 16
Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma.
PURPOSE We report stage specific followup guidelines based on our evaluation of the pattern of recurrence in 286 patients treated for local N0 or Nx renal cell carcinoma. MATERIALS AND METHODS WeExpand
  • 314
  • 14
Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study.
PURPOSE To evaluate ability of the University of California Los Angeles Integrated Staging System (UISS) to stratify patients with localized and metastatic renal cell carcinoma (RCC) into risk groupsExpand
  • 299
  • 13
Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival.
PURPOSE Since chronic inflammation contributes to tumorigenesis, we hypothesized that the risk and clinical outcome of bladder cancer (BC) might be modulated by genetic variations in inflammationExpand
  • 145
  • 12
Micropapillary bladder cancer
Micropapillary bladder carcinoma is a rare variant of urothelial carcinoma. To improve understanding of this disease, the authors performed a retrospective review of their experience.
  • 187
  • 11
Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high‐risk upper tract transitional cell carcinoma
The authors evaluated the incidence of pathologic downstaging and complete remission (CR) in patients with high‐grade ureteral and renal pelvic transitional cell carcinoma (TCC) (upper tract TCC) whoExpand
  • 178
  • 11
Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice.
Epidermal growth factor receptor (EGFR) regulates the growth and progression of human transitional cell carcinoma (TCC) of the bladder. We have shown that therapy targeting EGFR inhibited the growthExpand
  • 432
  • 10
  • PDF
The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy.
To determine the prognostic value of angiogenesis factor expression for patients with muscle-invasive transitional cell carcinoma (TCC) of the bladder treated with neoadjuvant methotrexate,Expand
  • 162
  • 10
  • PDF
Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer.
PURPOSE Currently, treatment recommendations for small-cell urothelial cancer (SCUC) are based on anecdotal case reports and small retrospective series. We now report results from the first phase IIExpand
  • 126
  • 10